Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of SPH3127 in Healthy Chinese Volunteers
NCT03128138Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sitokiren in hypertension (HTN) (6 arms), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoint: Assessment of safety parameters at 10 days. Started Dec 2016; status: completed.
02
Drugs
sitokiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03128138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128138.